Meeting News CoverageVideo

VIDEO: Anti–PD-1 immunotherapy confers ‘encouraging’ survival benefit in metastatic melanoma

NEW ORLEANS — Joseph Markowitz, MD, PhD, a medical oncologist in the department of cutaneous oncology at Moffitt Cancer Center, offers insights into a study presented at AACR Annual Meeting that showed more than one-third of patients with advanced melanoma treated with the anti–PD-1 antibody nivolumab (Opdivo, Bristol Myers Squibb) survived 5 years.

That is double the survival rate for patients with metastatic melanoma diagnosed between 2005 and 2011, according to SEER data.

“This study is very encouraging, but we also need future studies to figure out how to treat those 70% of patients who are not surviving to the 5-year mark,” Markowitz told HemOnc Today.

NEW ORLEANS — Joseph Markowitz, MD, PhD, a medical oncologist in the department of cutaneous oncology at Moffitt Cancer Center, offers insights into a study presented at AACR Annual Meeting that showed more than one-third of patients with advanced melanoma treated with the anti–PD-1 antibody nivolumab (Opdivo, Bristol Myers Squibb) survived 5 years.

That is double the survival rate for patients with metastatic melanoma diagnosed between 2005 and 2011, according to SEER data.

“This study is very encouraging, but we also need future studies to figure out how to treat those 70% of patients who are not surviving to the 5-year mark,” Markowitz told HemOnc Today.

    See more from American Association for Cancer Research Annual Meeting